Cure8 research brief
PG is often linked with IBD and other systemic conditions, so approaches that treat the underlying comorbidity can improve ulcer healing and lower relapse risk. Patients with IBD who develop PG may benefit from therapies chosen to control both gut and skin disease.
Adults with IBD who develop pyoderma gangrenosum, dermatologists, gastroenterologists, rheumatologists, and clinicians managing complex immune-mediated disease
This clinical review proposes managing PG by targeting comorbid systemic drivers — for example, using anti-TNF therapies when PG occurs alongside IBD, IL-1 blockade for autoinflammatory syndromes, or JAK inhibitors for overlap with inflammatory arthritis.
The paper summarizes clinical trials, case series, and real-world reports and recommends aligning dermatologic and systemic therapy to improve healing and reduce recurrence.
The review discusses biologic and small-molecule options (anti-TNF agents, IL-1 blockers, JAK inhibitors, IL-12/23 pathway agents) and emphasizes individualized treatment choices based on the patient’s comorbidities rather than empiric skin-directed therapy alone.
Clinical implications include closer coordination between dermatology, gastroenterology, and rheumatology when PG coexists with IBD or other systemic disease; selecting therapy that treats both the skin and the systemic condition may offer more durable ulcer healing.
This content is an academic review (Journal of the American Academy of Dermatology) and the provided text is an abstract-level summary; it synthesizes clinical trials, case series, and real-world reports rather than reporting new trial results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lung involvement is an underrecognized extraintestinal complication in IBD and can reflect disease activity, altered gut–lung immune signaling, or medication toxicity — distinguishing the cause is important for...
This review addresses cancer risk tied to IBD treatments, a common and important concern for people on long-term immunosuppression or advanced therapies.
Rheumatological EIMs (notably joint inflammation) are frequent in IBD and affect quality of life; inconsistent definitions and lack of validated PROs make it harder for patients and clinicians to understand and compare...
